{"id":"intravenous-tislelizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Immune-related colitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tislelizumab binds to programmed death receptor 1 (PD-1) on T cells, preventing interaction with its ligands (PD-L1 and PD-L2) expressed on tumor cells and immune cells. This blockade releases the brake on T cell activation, allowing enhanced proliferation, activation, and cytotoxic function against cancer cells. The drug is designed with a modified Fc region to minimize binding to FcγR receptors, potentially reducing immune-related adverse events compared to other PD-1 inhibitors.","oneSentence":"Tislelizumab is a monoclonal antibody that blocks PD-1 on T cells to enhance anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:46.017Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Hepatocellular carcinoma"},{"name":"Gastric or gastroesophageal junction cancer"},{"name":"Esophageal squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT06097962","phase":"EARLY_PHASE1","title":"Safety and Efficacy of NK510 to Treat NSCLC","status":"RECRUITING","sponsor":"Base Therapeutics (Shanghai) Co., Ltd.","startDate":"2023-07-01","conditions":"NSCLC","enrollment":12},{"nctId":"NCT05981703","phase":"PHASE1","title":"A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2023-09-21","conditions":"Advanced Solid Tumor, Solid Tumor","enrollment":217},{"nctId":"NCT07043400","phase":"PHASE3","title":"A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-08-27","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":351},{"nctId":"NCT07483359","phase":"PHASE2","title":"Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus","status":"NOT_YET_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2026-03","conditions":"Hepatocellular Carcinoma (HCC), Portal Vein Tumor Thrombus","enrollment":38},{"nctId":"NCT06233942","phase":"PHASE1","title":"Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-04-12","conditions":"Advanced Solid Tumor","enrollment":308},{"nctId":"NCT04379635","phase":"PHASE3","title":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2020-05-29","conditions":"Non Small Cell Lung Cancer","enrollment":453},{"nctId":"NCT06585488","phase":"PHASE1","title":"A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification","status":"RECRUITING","sponsor":"BeiGene","startDate":"2024-11-26","conditions":"Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer","enrollment":514},{"nctId":"NCT07472933","phase":"PHASE2","title":"Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-04-01","conditions":"Cancer of Biliary Duct","enrollment":44},{"nctId":"NCT06487858","phase":"PHASE1","title":"A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-07-16","conditions":"Solid Tumor","enrollment":75},{"nctId":"NCT06427941","phase":"PHASE1","title":"A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-07-23","conditions":"Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer","enrollment":140},{"nctId":"NCT05635708","phase":"PHASE2","title":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-03-07","conditions":"Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT07463248","phase":"PHASE2","title":"PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Wang Xin","startDate":"2026-03-05","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":64},{"nctId":"NCT07331155","phase":"PHASE2","title":"A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2026-02-26","conditions":"Advanced Solid Tumour","enrollment":110},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":"Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT06422520","phase":"PHASE1","title":"A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2024-07-08","conditions":"Advanced Solid Tumor","enrollment":120},{"nctId":"NCT04649385","phase":"PHASE1","title":"BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2021-03-04","conditions":"Advanced Solid Tumor","enrollment":157},{"nctId":"NCT07418190","phase":"PHASE2","title":"Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-01","conditions":"Relapsed/Refractory Follicular Lymphoma","enrollment":33},{"nctId":"NCT07414836","phase":"PHASE1","title":"A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"BeOne Medicines","startDate":"2026-04-30","conditions":"Advanced Solid Tumor","enrollment":84},{"nctId":"NCT06562647","phase":"NA","title":"SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Cell Origin Biotech (Hangzhou) Co., Ltd.","startDate":"2023-04-12","conditions":"Treatment Related Cancer, Ovarian Cancer","enrollment":2},{"nctId":"NCT07408609","phase":"PHASE2","title":"Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2026-02-26","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":114},{"nctId":"NCT05116085","phase":"PHASE2","title":"Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2022-01-26","conditions":"Colorectal Cancer","enrollment":33},{"nctId":"NCT07390383","phase":"PHASE2","title":"A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2026-03-25","conditions":"Advanced Solid Tumour","enrollment":110},{"nctId":"NCT05577702","phase":"PHASE2","title":"Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2023-03-08","conditions":"Non Small Cell Lung Cancer","enrollment":121},{"nctId":"NCT07396090","phase":"NA","title":"Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-20","conditions":"Advanced Solid Tumor","enrollment":13},{"nctId":"NCT07388758","phase":"PHASE2","title":"Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":37},{"nctId":"NCT07389187","phase":"EARLY_PHASE1","title":"Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mCRPC","enrollment":10},{"nctId":"NCT07383116","phase":"PHASE3","title":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","startDate":"2026-01-15","conditions":"Non Squamous Non-small Cell Lung Cancer","enrollment":500},{"nctId":"NCT07376499","phase":"PHASE2","title":"Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2026-01-25","conditions":"Small Cell Lung Cancer","enrollment":31},{"nctId":"NCT06199232","phase":"NA","title":"Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University","startDate":"2024-01-23","conditions":"Liver Metastasis Colon Cancer, ctDNA Genotype, MSS","enrollment":47},{"nctId":"NCT06206733","phase":"PHASE3","title":"ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AskGene Pharma, Inc.","startDate":"2024-01-25","conditions":"Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma","enrollment":780},{"nctId":"NCT06468280","phase":"PHASE2","title":"Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-11-08","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":84},{"nctId":"NCT07350070","phase":"PHASE2","title":"TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-31","conditions":"HCC, Liver Cirrhosis, Portal Hypertension","enrollment":78},{"nctId":"NCT07353294","phase":"PHASE1","title":"Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2026-01-01","conditions":"Bladder Urothelial Carcinoma, Lymph Node Metastasis","enrollment":12},{"nctId":"NCT07348107","phase":"PHASE1","title":"ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Daniel Breadner","startDate":"2026-02-15","conditions":"Advanced Pancreatic Ductal Adenocarcinoma","enrollment":10},{"nctId":"NCT07290985","phase":"PHASE2","title":"AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas","status":"NOT_YET_RECRUITING","sponsor":"American Association for Cancer Research","startDate":"2026-03-01","conditions":"Gastroesophageal Adenocarcinoma","enrollment":121},{"nctId":"NCT07328854","phase":"PHASE3","title":"40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-11-20","conditions":"Nasopharyngeal Carcinoma","enrollment":346},{"nctId":"NCT06849986","phase":"PHASE2","title":"IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-25","conditions":"Soft Tissue Sarcomas, Angiosarcoma, Fibrosarcoma","enrollment":45},{"nctId":"NCT07320105","phase":"PHASE4","title":"Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2026-01-15","conditions":"Non-Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT04425070","phase":"PHASE1, PHASE2","title":"A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma","status":"TERMINATED","sponsor":"Antengene Corporation","startDate":"2020-08-18","conditions":"Peripheral T-cell Lymphoma, NK/T-cell Lymphoma","enrollment":56},{"nctId":"NCT07304258","phase":"PHASE2","title":"A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University","startDate":"2025-12-12","conditions":"Gastric Cancer Peritoneal Metastases","enrollment":30},{"nctId":"NCT04294160","phase":"PHASE1","title":"A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-22","conditions":"BRAF V600 Colorectal Cancer","enrollment":122},{"nctId":"NCT07297030","phase":"PHASE2","title":"SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-12-20","conditions":"Rectal Cancer","enrollment":37},{"nctId":"NCT06825494","phase":"PHASE1, PHASE2","title":"Clinical Studies for the Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-04-08","conditions":"Advanced Solid Tumor","enrollment":194},{"nctId":"NCT07282262","phase":"PHASE2","title":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-05-01","conditions":"Biliary Tract Cancer","enrollment":300},{"nctId":"NCT05912816","phase":"PHASE2","title":"Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-06-10","conditions":"Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation, HER-2 ADC","enrollment":20},{"nctId":"NCT05886439","phase":"PHASE1, PHASE2","title":"LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-05-11","conditions":"Lung Cancer","enrollment":60},{"nctId":"NCT05516914","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2022-09-01","conditions":"Malignant Tumors","enrollment":490},{"nctId":"NCT07243691","phase":"NA","title":"Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2025-12-01","conditions":"Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT05238883","phase":"PHASE1","title":"A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"HiFiBiO Therapeutics","startDate":"2022-03-10","conditions":"Gastric Cancer, Renal Cell Carcinoma, Melanoma","enrollment":72},{"nctId":"NCT05789069","phase":"PHASE1","title":"A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"HiFiBiO Therapeutics","startDate":"2023-05-09","conditions":"Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer","enrollment":83},{"nctId":"NCT03412773","phase":"PHASE3","title":"A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"BeiGene","startDate":"2017-12-18","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":684},{"nctId":"NCT04215978","phase":"PHASE1","title":"Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2020-01-30","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":204},{"nctId":"NCT07111455","phase":"","title":"Prospective Cohort Study on Oral Microbiome Changes in Patients With Locally Advanced Oral Squamous Cell Carcinoma Following Neoadjuvant Chemoimmunotherapy","status":"RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2025-07-22","conditions":"Locally Advanced Oral Squamous Cell Carcinoma","enrollment":32},{"nctId":"NCT07185243","phase":"NA","title":"A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Hangzhou Converd Co., Ltd.","startDate":"2025-06-23","conditions":"Advanced Solid Tumors","enrollment":24},{"nctId":"NCT07070479","phase":"PHASE2","title":"Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-06-24","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":208},{"nctId":"NCT05267054","phase":"PHASE1, PHASE2","title":"Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab","status":"COMPLETED","sponsor":"BeiGene","startDate":"2022-04-25","conditions":"Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma","enrollment":53},{"nctId":"NCT05632939","phase":"PHASE1, PHASE2","title":"ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AskGene Pharma, Inc.","startDate":"2023-02-21","conditions":"Gastric Cancer, Gastroesophageal Cancer (GC)","enrollment":62},{"nctId":"NCT04047862","phase":"PHASE1","title":"Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-08-15","conditions":"Locally Advanced and Metastatic Solid Tumors","enrollment":446},{"nctId":"NCT06280313","phase":"","title":"Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension","status":"RECRUITING","sponsor":"Zhiyong Huang","startDate":"2024-03-15","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT03783442","phase":"PHASE3","title":"A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-12-11","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":649},{"nctId":"NCT07086456","phase":"PHASE2","title":"Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-20","conditions":"Surufatinib, Tislelizumab, Concurrent Chemoradiotherapy","enrollment":80},{"nctId":"NCT05604560","phase":"PHASE2","title":"A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lei Zheng","startDate":"2023-11-08","conditions":"Pancreatic Cancer","enrollment":25},{"nctId":"NCT05978102","phase":"PHASE1, PHASE2","title":"A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2023-08-23","conditions":"Advanced Solid Tumor","enrollment":183},{"nctId":"NCT07068178","phase":"PHASE2","title":"Evaluating the Efficacy of Hyperthermic Intraperitoneal Treatment to Enhance the Sensitivity of Immune Checkpoint Inhibitor in Patients With Advanced Ovarian Cancer： A Single-arm Study","status":"NOT_YET_RECRUITING","sponsor":"Jing Li","startDate":"2025-08","conditions":"HIPEC, Ovarian Serous Adenocarcinoma","enrollment":30},{"nctId":"NCT06379087","phase":"PHASE2","title":"Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC","status":"RECRUITING","sponsor":"Ji Yongling","startDate":"2024-05-01","conditions":"Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT04921358","phase":"PHASE3","title":"Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"BeiGene","startDate":"2021-07-27","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":377},{"nctId":"NCT06507371","phase":"PHASE3","title":"Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-07-29","conditions":"Rectal Cancer","enrollment":170},{"nctId":"NCT04746924","phase":"PHASE3","title":"A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2021-06-08","conditions":"Non-small Cell Lung Cancer, NSCLC","enrollment":662},{"nctId":"NCT06009861","phase":"PHASE2","title":"Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University Hospital of Stomatology","startDate":"2023-06-27","conditions":"Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma","enrollment":110},{"nctId":"NCT06966154","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-05-26","conditions":"Natural Killer/T-cell Lymphoma, Relapsed or Refractory Lymphoma Including ENKL","enrollment":68},{"nctId":"NCT05941481","phase":"PHASE2","title":"Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2023-06-10","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":21},{"nctId":"NCT06659042","phase":"PHASE2","title":"Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2024-11-20","conditions":"Lung Cancer, Non-Small Cell","enrollment":32},{"nctId":"NCT06093061","phase":"PHASE2","title":"Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2024-07-03","conditions":"Nasopharyngeal Carcinoma","enrollment":69},{"nctId":"NCT04579757","phase":"PHASE1, PHASE2","title":"Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Hutchmed","startDate":"2021-03-05","conditions":"Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors","enrollment":87},{"nctId":"NCT06497010","phase":"EARLY_PHASE1","title":"An Exploratory Study of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Advanced Solid Tumor Treatment","status":"RECRUITING","sponsor":"The Affiliated Hospital Of Guizhou Medical University","startDate":"2024-08-29","conditions":"Advanced Solid Tumor","enrollment":40},{"nctId":"NCT05494762","phase":"PHASE1","title":"Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"BeiGene","startDate":"2022-08-25","conditions":"Solid Tumor","enrollment":55},{"nctId":"NCT06951841","phase":"PHASE4","title":"Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2025-04-30","conditions":"Small Cell Lung Cancer","enrollment":31},{"nctId":"NCT06673693","phase":"PHASE2","title":"Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-15","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC), HNSCC","enrollment":24},{"nctId":"NCT05984602","phase":"PHASE1","title":"A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-07-14","conditions":"Pancreatic Cancer","enrollment":10},{"nctId":"NCT06431243","phase":"PHASE1, PHASE2","title":"A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2024-05-08","conditions":"Advanced Solid Tumor","enrollment":132},{"nctId":"NCT06860477","phase":"PHASE2","title":"Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-18","conditions":"Intrahepatic Cholangiocellular Carcinoma","enrollment":92},{"nctId":"NCT06914687","phase":"PHASE2","title":"Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-03-30","conditions":"Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Peritoneal Metastasis","enrollment":30},{"nctId":"NCT06416410","phase":"PHASE3","title":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2024-08-07","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":392},{"nctId":"NCT04802876","phase":"PHASE2","title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2021-04-12","conditions":"MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma","enrollment":184},{"nctId":"NCT05299476","phase":"PHASE2","title":"CAPOX + Bevacizumab + Tislelizumab Treating PD-L1 CPS < 5 Locally Advanced or Metastatic GEA","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2022-04-25","conditions":"Advanced Gastroesophageal Adenocarcinoma, First-line Therapy, PDL1 CPS < 5","enrollment":32},{"nctId":"NCT06881537","phase":"PHASE2","title":"CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-06-01","conditions":"Locally Recurrent Colorectal Cancer","enrollment":15},{"nctId":"NCT05464433","phase":"PHASE1, PHASE2","title":"Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-06-23","conditions":"Extranodal Natural Killer T Cell Lymphoma","enrollment":46},{"nctId":"NCT04401800","phase":"PHASE2","title":"Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2020-09-04","conditions":"Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma","enrollment":64},{"nctId":"NCT06344156","phase":"PHASE1","title":"Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-04-01","conditions":"Pancreatic Cancer, Adjuvant Therapy","enrollment":43},{"nctId":"NCT06835179","phase":"PHASE2","title":"SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-02","conditions":"Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC), RAS-mutant Colorectal Cancer","enrollment":28},{"nctId":"NCT03358875","phase":"PHASE3","title":"Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"BeiGene","startDate":"2017-11-30","conditions":"Non-small Cell Lung Cancer","enrollment":805},{"nctId":"NCT05532059","phase":"PHASE2","title":"Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-01-31","conditions":"Advanced Cholangiocarcinoma","enrollment":100},{"nctId":"NCT05823311","phase":"PHASE3","title":"Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-01","conditions":"Advanced Cholangiocarcinoma","enrollment":80},{"nctId":"NCT04732494","phase":"PHASE2","title":"Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-03-31","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":125},{"nctId":"NCT05972655","phase":"PHASE2","title":"Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2023-08-02","conditions":"Low Rectal Cancer","enrollment":32},{"nctId":"NCT06749886","phase":"PHASE2","title":"An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2024-11-19","conditions":"Lung Cancer","enrollment":22},{"nctId":"NCT06749860","phase":"PHASE2","title":"Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2024-02-02","conditions":"Lung Cancer","enrollment":58},{"nctId":"NCT06704620","phase":"PHASE3","title":"Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-12","conditions":"Advanced and Metastatic NSCLC","enrollment":430},{"nctId":"NCT04276493","phase":"PHASE1, PHASE2","title":"Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab","status":"COMPLETED","sponsor":"BeiGene","startDate":"2020-03-26","conditions":"Breast Cancer, Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":71}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BGB-A317","TEVIMBRA®","immunotherapy"],"phase":"phase_3","status":"active","brandName":"Intravenous Tislelizumab","genericName":"Intravenous Tislelizumab","companyName":"BeOne Medicines","companyId":"beone-medicines","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tislelizumab is a monoclonal antibody that blocks PD-1 on T cells to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Hepatocellular carcinoma, Gastric or gastroesophageal junction cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}